Akums Drugs introduces DCGI approved medication for Hypertension
(1 votes, average: 5.00 out of 5)
Loading...
Pharma major Akums Drugs and Pharmaceuticals has introduced Amlodipine, Telmisartan & Metoprolol (ER) Film Coated Tablets, a fixed-dose combination (FDC) medication for the management of uncontrolled essential hypertension with stable coronary artery disease. This FDC integrates the therapeutic benefits of three well-established medications into a single, convenient tablet, offering a comprehensive approach to blood pressure control.
With the approval from the Drugs Controller General of India (DCGI), Amlodipine, Telmisartan & Metoprolol (ER) Film Coated Tablets represent an advancement in cardiovascular care. “This new FDC embodies our commitment to improving patient outcomes and enhancing the quality of life for individuals battling hypertension,” states Sandeep Jain, MD, Akums Drugs and Pharmaceuticals.
Hypertension, a pervasive health challenge associated with significant mortality and long-term morbidity, remains a formidable obstacle in healthcare worldwide. As a major risk factor for vascular diseases such as cerebrovascular disease, ischemic heart disease, cardiac failure, and renal failure, hypertension’s impact on global health cannot be overstated.
By combining the therapeutic benefits of calcium channel blockers, angiotensin II receptor antagonists, and beta-adrenergic blockers, this FDC offers a comprehensive approach to blood pressure control. “We believe that this formulation has the potential to improve the way we manage hypertension” adds Sanjeev Jain, MD, Akums Drugs and Pharmaceuticals.
The individual mechanism of action of each component contributes to the FDC’s efficacy in hypertension management. Amlodipine, by blocking voltage-dependent L-type calcium channels, induces vasodilation and decreases vascular smooth muscle contractility, thereby lowering blood pressure. Telmisartan selectively inhibits the angiotensin II AT1 receptor subtype, promoting blood vessel relaxation. Metoprolol (ER), a cardio-selective beta-1-adrenergic receptor inhibitor, reduces cardiac output through negative inotropic and chronotropic effects.
Single-pill triple combinations of different classes of drugs with complementary mechanisms of action help to treat patients to a goal with improved efficacy and better adherence to treatment. Thus, this fixed-dose of triple medications used as a single pill will improve patient’s dose compliance leading to better long-term BP control.
